Login or Register to make a submission.

Submission Preparation Checklist

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.
  • All authors have read the manuscript before submission. Any person only involved in writing the manuscript will not be the author or corresponding author. I have entered all the name of authors with all information and ORCID iD.

    We will submit the pdf files of Conflict of Interest for each author separately by their own email.

  • The submission has not been previously published, nor is it before another journal for consideration. Any content(s) of the table or figure is not published anywhere.

  • The submission file is in Microsoft Word document file format. E-mail address of all the authors nust be included.

  • When available, the URLs to access references online are provided, including those for open access versions of the reference. The URLs are ready to click (e.g., http://pkp.sfu.ca).

  • The text adheres to the stylistic and bibliographic requirements outlined in the Author Guidelines, which is found in About the Journal.

  • If submitting to a peer-reviewed section of the journal, the instructions in Ensuring a Blind Review) have been followed.

Author Guidelines

Selection of Bangladesh Journal of Pharmacology

Interested in submitting your manuscript to this journal? We recommend that you review the About the Journal page as well as Submission section. Authors need to register with the journal prior to submitting or, if already registered, can simply log in and begin the six-step process.

Before submitting your manuscript to the Bangladesh Journal of Pharmacology, you have to consider the advantages and disadvantages of selecting this journal.

The advantages are:

  1. Open access journal (each article in both pdf and HTML format)
  2. Peer reviewed journal
  3. Web of Science impact factor (2 years): 0.811 (2018)
  4. Online submission and tracking of your manuscript
  5. Article available online immediately after acceptance
  6. Each article has a cover page with DOI and matrices
  7. Copyright to authors (Creative Commons Attribution 4.0)
  8. No fee for manuscript submission, article processing or publication

The disadvantages are:

  1. Only online version. No hard copy
  2. Requires video clip of methodology (one method in detail) in case of research article
  3. Both internal review (by the editorial board member) and external peer review
  4. Annual acceptance rate is around 10% (ten percent)
  5. About 120 days are required from submission to publication
  6. You have to submit ORCID ID with information, fill-up the Conflict of Interest form during acceptance of the manuscript
  7. Plagiarism check of each article by a software “Plagiarism Detector”
  8. Each article is checked before publication to identify the grammatical mistake using Grammarly.com
  9. Article may be retracted if needed
  10. Need knowledge about online submission of manuscript (e-mail submission is not allowed); skill in preparing video with subtitle

Type of manuscript

The number of disadvantages are more than the advantages. Even then if you decide to submit your manuscript, follow the policies and formatting guidelines.

Bangladesh Journal of Pharmacology publishes the following article types:

  • Mini-review 
  • Meta-analysis
  • Visual Experiment
  • Clinical trial
  • Research Article 
  • Letter to the Editor

Once you decided your type of manuscript, then browse a few published papers and watch video clips to understand the format. 

Preparing your manuscript

Write manuscript according to our journal style. Manuscript must be typed in MSWord file in Font "Book Antique", Size 9 point and double space. The use of other fonts may lead to missing symbols within the text. Text within the Figure will be Arial, 7 point.

Research Article: All text (title page, abstract, body and references) should be submitted as one document.

Title page: The title page should:

  1. Present a title
  2. List the full names and institutional addresses for all authors
  3. Name of the corresponding author with email address

Abstract: The abstract should not be more than 150 words. There will be a single paragraph. Avoid abbreviations, diagrams, and references within the abstract.

Keywords: Three to ten keywords representing the main content of the article.

Text: The body of the text in the Research Article should be divided into the following sections: Introduction, Materials and Methods, Results, Discussion and Conclusion. Introduction will be within 500 words. In the Materials and Methods section, one of the methodologies must be in the video form that will help the reader to understand the quality of your methodology. Initially it is not necessary to submit the video component. The editor will inform the corresponding author to make and submit the video component of one of the methodologies. The protocol of one of the methodologies must be written in detail. The Results section should not be merged with the Discussion section. After the Conclusion section, you have to write the Funding Source, Ethical Issue, Conflict of Interest and Acknowledgement(s).

Human and Animal Rights: When reporting experiments on human subjects, authors have to write whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. When reporting experiments on animals, authors should indicate whether the institutional and national guide for the care and use of laboratory animals was followed. The work will be rejected if there is lack of evidence. 

Funding: The source(s) of funding for the research published must be declared. The role of funding body in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript must be declared.

Conflict of interest: All authors of the submitted manuscript are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within two years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. We customized the format of ICMJE (International Committee of Medical Journal Editors) conflict of interest form. We provided that form to fill-up by each author to submit separately from each author's email after completion of the peer review of the manuscript.

Acknowledgements: Acknowledgements, if any, should be placed at the end of the body of the text and be limited to no more than 100 words. This section may be used to acknowledge the help of those who do not qualify for authorship or to acknowledge funding, donated resources, or significant material contributions to the research.

References: All references should appear at the end of the article in alphabetical order. Be sure to cite all references in the text. Include only references that are actually cited in the text. Examples of the Journal's style are listed below.

Book Chapter: Goadsby PJ. Pathophysiology of headache. In: Wolff's headache and other head pain. Silberstein SD, Lipton RB, Dalessio DJ, (eds). 7th ed. Oxford, England, Oxford University Press, 2001, pp 57-72.

Journal Article: Bullard RD, Wright BH. The quest for environmental equity: Mobilizing the African-American community for social change. Soc Nat Res. 1990; 3: 301-11. List all authors; do not use "et al".

Personal Communications: Reference to personal communications should be avoided.

Websites: Please avoid it. 

Illustrations: Illustrations submitted (line drawings, halftones, photos, photomicrographs, etc.) should be clean digital files. Digital files are recommended for highest quality reproduction and should follow these guidelines:

  • 300 dpi or higher
  • sized to fit on journal page
  • EPS, TIFF, and PDF formats are preferred. JPG and GIF formats are acceptable
  • submit as separate files, not embedded in text files

Tables and Figures: Data within the table should be not more than one digit after dot. All illustrations, figures, and tables are placed at the end of the manuscript. A short descriptive title should appear above each table with a clear legend and any footnotes suitably identified below. All units must be included. Provide two sets of Figure. One with completely labeled and another without label. Captions should be typed, double-spaced, on a separate sheet. 

Footnotes: For uniformity of style, authors should use symbols for footnotes such as "a" superscript, §, Please avoid one star "*", two star "**", three star "***".  

Letter to the Editor: There will be no abstract and subheadings. Text will be within 1,500 words with one/two Figures or Tables with up to 10 references. It will not be peer reviewed and published rapidly. 

Mini-Review: Mini-review is usually solicited by the editor but we also consider unsolicited manuscript. Please send pre-submission enquiry (with abstract) to the editor before writing a mini-review for Bangladesh Journal of Pharmacology. During submission of manuscript you must mention your link of "Google scholar citation".

Visual Experiment: You can publish your scientific experimental method or protocol in video form. It will be peer reviewed before make it online. Visual Experiment contains abstract, introduction, protocol/procedure, chemicals, prepared solutions with strength, Equipment, cautions, discussion and references.

Clinical Trial: Please use the reporting guidelines provided by the Equator Network (http://www.equator-network.org/reporting-guidelines/consort/) while writing the manuscript on clinical trial. You have to submit the a) Data-Availability Statement and b) registration number from the https://register.clinicaltrials.gov during submission of the manuscript. The Editor-in-Chief may request to upload the following files into www.osf.io :

a) all raw data, b) filled consent forms, c) approved protocol, d) approval letter of your clinical trial obtained from the IRB/Ethical Committee, and other images

English Language Editing: You have to be careful about the English language of your manuscript if your mother tongue is not English. Submission of manuscript with incorrect English interrupts the review process of your manuscript either by the Editor or reviewer. Therefore, we have the following suggestions while preparing the manuscript: a) Ask your colleague who is a native English speaker to check the English grammar of your manuscript, b) Use free or paid software to check the English grammar. For example, www.grammarly.com or c) Use the professional language editing service. The use of a language editing service is not a requirement for publication in this journal and does not guarantee that the manuscript will be selected for peer review or accepted.

Plagiarism, duplication and misconduct: The journal has policies against any kind of plagiarism, duplication and misconduct. Each manuscript will be screened for plagiarism by a plagiarism detection software. The manuscript will be rejected with notification to the author(s)' institute in case of plagiarism detected more than 10%. If plagiarism, duplication or misconduct is seen after publication at any time, retraction will be done and notification to the author(s)' institute will also be subsequently done.

Informed Consent Guidelines: The research article related to clinical trial must have a statement that an informed consent document was filled-up by the volunteer/patient. The subjects in the study must participate willingly, having been adequately informed about the research.  In case of children, the researcher must first obtain the permission of parents in addition to the consent of the children. Informed consent documents should be written at a level appropriate to the subject population, generally at an 8th grade reading level. A best practice is to have a colleague or friend read the informed consent document for comprehension before submission with the IRB application. 

Submission of Manuscripts: Register yourself as an author and submit the manuscript by clicking online submission. Submit the name of all authors with all information (including ORCID iD). The information in ORCID about each author must be at least for the last 5 years. Authors must give three to four keywords that identify the most important subjects covered by the paper. On the title page, include full names of all authors (no initial), academic and/or other professional affiliations (where the work was done), the name of corresponding author (supervisor or student directly involved in research work) should be sent. Any person only involved in writing the manuscript will not be an author or corresponding author. Upload the text file. If it is more than 3 MB, then remove the illustrations and upload it separately. You have to upload illustration and video clips to www.drive.google.com and share the email of the Editor (dgdabd@gmail.com). 

Any question about a manuscript must be written to the editor who is handling the manuscript.

Bangladesh Journal of Pharmacology receives more submissions than it can publish (10-12 out of 100). It is unfortunate to say that when we accept one paper that means another good paper must be rejected. 

Initial Internal Editorial Review: To avoid unnecessary delay to get a decision about the manuscript, initially we do internal editorial review. It takes about 3-10 days. Using this method, about one-third of all submitted manuscripts are rejected without peer-review. That is, initial rejection is often much quicker. In that case, authors have the option to submit their manuscript to another journal without unnecessary delay. The usual reasons for rejection at this stage are a) insufficient originality, b) the absence of important message to the scientific community, c) not written according to our journal style, or d) ill-written. We may screen a manuscript by reading only the abstract. So, the abstract should be structured (without subheading and paragraph), clear, complete and accurate as possible.

Peer-reviewed manuscripts: Among the all submitted manuscripts, Mini-review, Meta-analysis, Clinical Trial, Visual Experiment and Research Article are peer-reviewed. One exception is that “Letter to the Editor” is not peer-reviewed.

External Peer Review: If any manuscript passes the first step and meets the Criteria for Publication, then the manuscript is sent to two independent external reviewers for comment/advice. The whole process is single-blinded. This is done in order to save the time of the authors as well as reduce the workload of the peer-reviewers.

Selection of Reviewers: Reviewer selection is the critical and important part to the publication process. The choice of selection is based on several factors, including a) expertise, b) reputation, c) capability of giving recommendations, d) giving enough time to review and e) our own previous experience of a reviewer's characteristics. For example, the reviewer who is slow, careless, or do not provide definite comment is avoided.

Timing: Bangladesh Journal of Pharmacology is committed to give rapid editorial decision and publication. To achieve the goal, an efficient editorial process is a valuable service both to our authors and to the scientific community as a whole. Therefore, we request the reviewers to respond promptly within three days to agree to do the review process. If a reviewer does not agree/respond to review a manuscript, then we request another reviewer. Once a reviewer agrees to review, the maximum allocated time period of review is 3 weeks. A soft reminder email is sent to the reviewer when the allocated time is over. This process performs well.

Editorial Decision: The editor takes the final decision based on the reviewers' comment. The decision may be any one of the followings:

a) Accept for Publication, with or without any minor editorial revision

b) Inform the corresponding author to Revise the Manuscript to address the specific concerns before a final decision is reached. Submission of revised manuscript does not ensure the acceptance

c) Reject, but inform the corresponding author that further write-up might justify a Resubmission

d) Decline Submission, typically on grounds of specialist interest, lack of novelty, insufficient conceptual advance or major technical and/or interpretational problems

Confidential: Editor, editorial board members, authors and reviewers keep confidential of all details of the editorial and peer review process on submitted manuscripts. Even identities of the reviewer are not disclosed to the corresponding author. In addition, reviewers maintain the confidentiality of the manuscript. 

Proofs: All proofs must be corrected and returned to the publisher as early as possible. Only correction of typographical errors is permitted at the proof stage. 

Authorship: The corresponding author is responsible for all the information of these forms. He/she will confirm that all the authors have read the manuscript before submission. The following person(s) will be authors:

  • concept. research question and study design
  • data collection or processing

Any person only involved in writing the manuscript or analyzing the data will not be the author or corresponding author particularly in Research Article.

Errata guidelines: If author(s) identify a significant error after publication of the online versions of the article, it will be corrected, and an erratum will be published online. A significant error means incorrect information or mistake that changes the meaning of the article, equation, table, or figure. We will consider a spelling error that changes the meaning of the paper to be significant. We will also consider a misspelling of an author’s name or the name of a reference significant. Typographical errors that are still readable, grammar corrections, and discoveries made after the article was published are usually not considered to be grounds for an erratum. We will do our best to correct any errors found regardless of when they appeared online.

Deposited: All articles published in the Bangladesh Journal of Pharmacology are deposited with Crossref.

Crossref Content Registration logo

Privacy Statement

Bangladesh Journals Online (BanglaJOL) is a member of the Ubiquity Partner Network coordinated by Ubiquity Press. According to the EU definitions, BanglaJOL is the data controller, and Ubiquity Press are the service providers and data processors. Ubiquity Press provide the technical platform and some publishing services to BanglaJOL and operate under the principle of data minimisation where only the minimal amount of personal data that is required to carry out a task is obtained.

More information on the type of data that is required can be found in Ubiquity Press’ privacy policy below.

Ubiquity Press Privacy Policy

We take seriously our duty to process your personal data in a fair and transparent way. We collect and manage user data according to the following Privacy Policy. This document is part of our Terms of Service, and by using the press portal, affiliated journals, book, conference and repository websites (the “Websites”), you agree to the terms of this Privacy Policy and the Terms of Service. Please read the Terms of Service in their entirety, and refer to those for definitions and contacts.

What type of personal data do we handle?

There are four main categories of personal data stored by our journal platform, our press platform, and our book management system; Website User data, Author data, Reviewer data and Editor data.

The minimum personal data that are stored are:

  • full name
  • email address
  • affiliation (department, and institution)
  • country of residence

Optionally, the user can provide:

  • salutation
  • gender
  • associated URL
  • phone number
  • fax number
  • reviewing interests
  • mailing address
  • ORCiD
  • a short biography
  • interests
  • Twitter profile
  • LinkedIn profile
  • ImpactStory profile
  • profile picture

The data subjects have complete control of this data through their profile, and can request for it to be removed by contacting info@ubiquitypress.com

What do we do to keep that data secure?

We regularly backup our databases, and we use reliable cloud service providers (Amazon, Google Cloud, Linode) to ensure they are kept securely. Backups are regularly rotated and the old data is permanently deleted. We have a clear internal data handling policy, restricting access to the data and backups to key employees only. In case of a data breach, we will report the breach to the affected users, and to the press/journal contacts within 72 hours.

How do we use the data?

Personal information is only used to deliver the services provided by the publisher. Personal data is not shared externally except for author names, affiliations, emails, and links to ORCiD and social media accounts (if provided) in published articles and books which are displayed as part of the article/book and shared externally to indexes and databases. If a journal operates under open peer review then the reviewer details are published alongside the reviewer details.

How we collect and use your data:

1. When using the website

1.1 what data we collect

  • When you browse our website, we collect anonymised data about your use of the website; for example, we collect information about which pages you view, which files you download, what browser you are using, and when you were using the site.
  • When you comment on an article or book using Disqus, we are not collecting, controlling or processing the data. More details on the DISQUS privacy policy can be found on their website.
  • When you annotate an article or book, this is done via a 3rd party plugin to the website called Hypothes.is. In using this plugin we are not collecting, controlling or processing the data. More details on the Hypothes.is privacy policy can be found on their website.

1.2 why we collect the data

  • We use anonymised website usage data to monitor traffic, help fix bugs, and see overall patterns that inform future redesigns of the website, and provide reports on how frequently the publications on our site have been accessed from within their IP ranges.

1.3 what we do (and don’t do) with the data

  • We do not collect personal information that can be used to identify you when you browse the website.
  • We currently use Google Analytics for publication reports, and to improve the website and services through traffic analysis, but no personal identifying data is shared with Google (for example your computer’s IP is anonymised before transmission).

1.4 what to do if you want to get a copy of your data, or want your data to be removed

  • Please contact info@ubiquitypress.com to request a copy of your data, or for your data to be removed/anonymised.

2. When registering as an author, and submitting an article or book

2.1 what data we collect

  • When registering an account we ask you to log in and provide certain personal information (such as your name and email address), and there is the option to register using an ORCiD which will pre-fill the registration form.
  • As part of submitting an article for publication, you will need to provide personally identifying information which will be used for the peer review process, and will be published. This can include ‘Affiliation’, ‘Competing interests’, ‘Acknowledgements’.

2.2 why we collect the data

  • Registering an account allows you to log in, manage your profile, and participate as an author/reviewer/editor. We use cookies and session information to streamline your use of the website (for example in order for you to remain logged-in when you return to a journal). You can block or delete cookies and still be able to use the websites, although if you do you will then need to enter your username and password to login. In order to take advantage of certain features of the websites, you may also choose to provide us with other personal information, such as your ORCiD, but your decision to utilize these features and provide such data will always be voluntary.
  • Personal data submitted with the article or book is collected to allow follow good publication ethics during the review process, and will form part of the official published record in order for the provenance of the work to be established, and for the work to be correctly attributed.

2.3 what we do (and don’t do) with the data

  • We do not share your personal information with third parties, other than as part of providing the publishing service.
  • As a registered author in the system you may be contacted by the journal editor to submit another article.
  • Any books published on the platform are freely available to download from the publisher website in PDF, EPUB and MOBI formats on the publisher’s site.
  • Any personal data accompanying an article or a book (that will have been added by the submitting author) is published alongside it. The published data includes the names, affiliations and email addresses of all authors.
  • Any articles published on the platform are freely available to download from the publisher website in various formats (e.g. PDF, XML).
  • Ubiquity Press books and articles are typeset by SiliconChips and Diacritech.This process involves them receiving the book and book associated metadata and contacting the authors to finalise the layout. Ubiquity Press work with these suppliers to ensure that personal data is only used for the purposes of typesetting and proofing.
  • For physical purchases of books on the platform Ubiquity Press use print on demand services via Lightning Source who are responsible for printing and distribution via retailers. (For example; Amazon, Book Repository, Waterstones). Lightning Source’s privacy policy and details on data handling can be found on their website.

2.4 why we store the data

  • We store the account data so that you may choose to become a reviewer and be able to perform those tasks, or to become an author and submit an article and then track progress of that article.
  • Published personal data that accompanies an article or a book forms part of the official published record in order for the provenance of the work to be established, and for the work to be correctly attributed.

2.5 what to do if you want to get a copy of your data, or want your data to be removed

  • You are able to view, change and remove your data associated with your profile. Should you choose to completely delete your account, please contact us at support@ubiquitypress.com and we will follow up with your request as soon as possible.
  • To conform to publication ethics and best practice any personal data that is published alongside an article or book cannot be removed. If you have a query about a publication to which you are attributed please contact info@ubiquitypress.com

3. When registering as a reviewer

3.1 what data we collect

  • To become a reviewer you must first register as a user on the website, and set your preference that you would like to be considered as a reviewer. No new personal data is collected when a registered user elects to become a reviewer.
  • When registering an account we ask you to log in and provide certain personal information (such as your name and email address), and there is the option to register using an ORCiD which will pre-fill the registration form.
  • Reviewers can also be registered by editors who invite them to review a specific article. This requires the editor to provide the reviewer’s First Name, Last Name, and Email address. Normally this will be done as part of the process of inviting you to review the article or book.
  • On submitting a review, the reviewer includes a competing interest statement, they may answer questions about the quality of the article, and they will submit their recommendation.

3.2 why we collect the data

  • The data entered is used to invite the reviewer to peer review the article or book, and to contact the reviewer during and the review process.
  • If you submit a review then the details of your review, including your recommendation, your responses to any review form, your free-form responses, your competing interests statement, and any cover letter are recorded.

3.3 what we do (and don’t do) with the data

  • This data is not shared publicly and is only accessible by the Editor and system administrators of that journal or press.
  • The data will only be used in connection with that journal or press.
  • Data that is retained post final decision is kept to conform to publication ethics and best practice, to provide evidence of peer review, and to resolve any disputes relating to the peer review of the article or book.
  • For journals or presses that publish the peer reviews, you will be asked to give consent to your review being published, and a subset of the data you have submitted will become part of the published record.

3.4 what to do if you want to get a copy of your data, or want your data to be removed

  • If you would no longer like to be registered as a reviewer you can edit your profile and tick the box ‘stop being a reviewer’. This will remove you from the reviewer database, however any existing reviews you may have carried out will remain.
  • If you have been contacted by an editor to peer review an article this means that you have been registered in the system. If you would not like to be contacted for peer review you can reply to the email requesting that your data be deleted.

4. When being registered as a co-author

4.1 what data we collect

  • Co-author data is entered by the submitting author. The submitting author will already have a user account. According to standard publishing practice, the submitting author is responsible for obtaining the consent of their co-authors to be included (including having their personal data included) in the article/book being submitted to the journal/press.
  • The requested personal data for co-authors are at the bare minimum; first name, last name, institution, country, email address. This can also include; ORCID ID, Title, Middle Name, Biographical Statement, Department, Twitter Handle, Linkedin Profile Name or ImpactStory ID.

4.2 why we collect the data

  • Assuming that it is accepted for publication, this data forms part of the official published record in order for the provenance of the work to be established, and for the work to be correctly attributed.
  • Author names, affiliations and emails are required for publication and will become part of the permanent cited record.

4.3 what we do (and don’t do) with the data

  • The co-author’s personal data is stored in the author database. This personal data is only used in relation to the publication of the associated article.
  • Any co-author data collected is added to the author database and is only used in association with the article the user is co-author on.

4.5 what to do if you want to get a copy of your data, or want your data to be removed

  • To receive a copy of your data, please contact info@ubiquitypress.com
  • To conform to publication ethics and best practice any personal data that is published alongside an article or book cannot be removed. If you have a query about a publication to which you are attributed please contact info@ubiquitypress.com

5. When signing-up to receive newsletters

5.1 what data we collect

  • We require you to include your name and email address

5.2 why we collect and store the data, and for how long

  • This data would be collected to keep you updated with any news about the platform or specific journal

5.3 what we do (and don’t do) with the data

  • We use mailchimp to provide our mailing list services. Their privacy policy can be found here

5.4 what to do if you want to get a copy of your data or want your data to be removed

  • All emails sent via our newsletter client will include a link that will allow you to unsubscribe from the mailing list

Notification about change of ownership or of control of data

We may choose to buy or sell assets. In the case that control of data changes to or from Ubiquity Press and a third party, or in the case of change of ownership of Ubiquity Press or of part of the business where the control of personal data is transferred, we will do our best to inform all affected users and present the options.

(Updated: 18 May 2018)